NasdaqCM - Nasdaq Real Time Price USD

Lantern Pharma Inc. (LTRN)

5.38

-0.39

(-6.76%)

At close: April 24 at 4:00 PM EDT

5.21

-0.17

(-3.16%)

After hours: April 24 at 7:10 PM EDT

Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

DALLAS, April 24, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical-stage drug programs, announced today that – the company has launched Webinar Wednesdays, a webinar series that focuses on areas of high oncology drug development interest with leading physicians, scientists and Lantern collaborators in drug developmen

Business Wire 12 hours ago

LTRN
-6.76%
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

DALLAS, April 22, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical-stage drug programs, announced today that – the company has received regulatory approval to expand its Harmonic™ trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer (NSCLC) in never-smokers in both Japan and Taiwan. Approxi

Business Wire 2 days ago

LTRN
-6.76%
Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript

Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript March 18, 2024 Lantern Pharma Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to our Fourth Quarter and Year End 2023 Earnings Call. As a reminder, […]

Insider Monkey last month

LTRN
-6.76%
LTRN: 2023 Results

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Lantern Pharma, Inc (NASDAQ:LTRN) reports full year 2023 financial results and achievements. Over the last few months, the company has been granted yet another orphan designation, strengthened its management team and progressed in its antibody drug conjugate (ADC) program. It has also participated in scientific and investor

Zacks Small Cap Research last month

LTRN
-6.76%
Lantern Pharma Inc Reports Progress and Financials for FY 2023

Advancements in AI-Guided Drug Candidates and Financial Stability Highlighted

GuruFocus.com last month

LTRN
-6.76%
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

DALLAS, March 18, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2023.

Business Wire last month

LTRN
-6.76%
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

DALLAS, March 15, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced the dosing of the first two patients in the Phase 1 clinical trial evaluating Lantern’s investigational new drug LP-284 in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle cell lymp

Business Wire last month

LTRN
-6.76%
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

DALLAS, March 11, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2023 financial results webcast on Monday, March 18, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Business Wire last month

LTRN
-6.76%
11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds

In this article, we discuss 11 best artificial intelligence stocks under $20. If you want to skip our discussion on the AI industry, head directly to 5 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds. As we move into 2024, the impact of artificial intelligence is expected to grow even further, following the […]

Insider Monkey last month

NOKIA.HE

LTRN
-6.76%
INOD
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

DALLAS, March 05, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW. The conference will be on Thursday, March 7th, and is a virtual event.

Business Wire last month

LTRN
-6.76%
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

DALLAS, March 04, 2024--Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced a series of important milestones related to the development, size, and advancement of RADR® -- its proprietary AI platform focused on transforming the cost, pace, and timeline of oncology drug development.

Business Wire last month

LTRN
-6.76%
3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom

In the rapid-tech space, innovation is an opportunity. The article lists three AI powerhouses that are breeding an unprecedented surge. These companies are the AI powerhouses of industry. As the world reaches a new age of AI, these companies are creating to ride the waves through technological advancements. Their strategies are based on the nexus of AI and related industry evolutions. Here, strategic acquisitions, operational edge, and groundbreaking technologies converge to bring in massive pri

InvestorPlace 2 months ago

LTRN
-6.76%
MITK
LTRN: Spotlighting ADCs & Another Orphan

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT We update investors on Lantern Pharma, Inc’s (NASDAQ:LTRN) recent communications since the third quarter report back in November. The company has been granted yet another orphan designation, this time for LP-284 in high grade B-cell lymphomas. It also added Chief Medical Officer, Dr. Marc Chamberlain, to its Starlight

Zacks Small Cap Research 2 months ago

LTRN
-6.76%
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

DALLAS, February 15, 2024--Press release about Lantern Pharma's ADC program focused on cryptophycin drug-payload ADC being developed in collaboration with Bielefeld.

Business Wire 2 months ago

LTRN
-6.76%
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 2 months ago

LTRN
-6.76%
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

DALLAS, January 17, 2024--Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D. has joined Starlight as its Chief Medical Officer. Dr. Chamberlain will oversee Starlight’s clinical operations, which currently include planned clinical trials for glioblastoma and other high-grade gliomas,

Business Wire 3 months ago

LTRN
-6.76%
The 3 Most Undervalued AI Penny Stocks to Buy in December

It’s easy to understand why investors remain curious about AI penny stocks in December and beyond. Leading companies in the artificial intelligence (AI) industry have multiplied in value in 2023. The AI market was worth roughly $515 billion in 2023. By 2030, it is expected to more than quadruple in value, reaching $2.025 trillion. That equates to a compound annual growth rate of more than 21% over the period. So, it’s easy to see why investors are scrambling to invest in undervalued penny in the

InvestorPlace 4 months ago

GFAIW

LTRN
-6.76%
HIMX
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

DALLAS, November 30, 2023--FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL). This is the second ODD for LP-284.

Business Wire 4 months ago

LTRN
-6.76%
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript

Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Good afternoon, and welcome to our Third Quarter 2023 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode. We will open the call for questions and answers after our management’s presentation. A webcast […]

Insider Monkey 5 months ago

LTRN
-6.76%
LTRN: Three Assets in the Clinic in 3Q:23

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Third Quarter 2023 Financial and Operational Results On November 8, 2023, Lantern Pharma, Inc. (NASDAQ:LTRN) announced 3Q:23 financial and operational results, filed its Form 10-Q with the SEC and hosted a video webcast to review accomplishments. Since Lantern’s second quarter update, it has added new sites in Asia for its

Zacks Small Cap Research 5 months ago

LTRN
-6.76%

Performance Overview

Return	LTRN	S&P 500
YTD	+25.70%	+6.33%
1-Year	+10.25%	+22.70%
3-Year	-67.49%	+21.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Lantern Pharma Inc. (LTRN)

Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript

LTRN: 2023 Results

Lantern Pharma Inc Reports Progress and Financials for FY 2023

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom

LTRN: Spotlighting ADCs & Another Orphan

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

The 3 Most Undervalued AI Penny Stocks to Buy in December

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript

LTRN: Three Assets in the Clinic in 3Q:23

Performance Overview